Courier Capital LLC Gilead Sciences, Inc. Transaction History

Courier Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	SELL	$71.58 - $87.29 $7,158 - $8,729	-100 Reduced 1.1%	8,965 $656,000
Q4 2023 Jan 17, 2024	SELL	$73.27 - $83.09 $12,089 - $13,709	-165 Reduced 1.79%	9,065 $734,000
Q3 2023 Oct 13, 2023	SELL	$73.94 - $80.67 $1,996 - $2,178	-27 Reduced 0.29%	9,230 $691,000
Q2 2023 Jul 31, 2023	BUY	$76.01 - $86.7 $703,624 - $802,581	9,257 New	9,257 $713,000
Q3 2018 Oct 12, 2018	SELL	$71.28 - $78.92 $2.53 Million - $2.81 Million	-35,563 Closed	0 $0
Q2 2018 Jul 19, 2018	SELL	$64.88 - $75.68 $360,213 - $420,175	-5,552 Reduced 13.5%	35,563 $2.52 Million
Q1 2018 Apr 27, 2018	SELL	$72.84 - $88.8 $57,980 - $70,684	-796 Reduced 1.9%	41,115 $3.1 Million
Q4 2017 Jan 25, 2018	SELL	$71.15 - $83.52 $730,852 - $857,917	-10,272 Reduced 19.68%	41,911 $3 Million
Q3 2017 Nov 03, 2017	BUY	$72.11 - $85.47 $3.76 Million - $4.46 Million	52,183	52,183 $4.23 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Courier Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Courier Capital LLC with notifications on news.